Published in Invest New Drugs on September 22, 2007
Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J (2010) 2.57
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer (2008) 2.35
Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. J Clin Oncol (2016) 1.53
Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res (2012) 1.29
Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. Invest New Drugs (2009) 1.12
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin. Br J Cancer (2012) 1.06
An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials. PLoS One (2014) 1.01
"Classical 3 + 3 design" versus "accelerated titration designs": analysis of 270 phase 1 trials investigating anti-cancer agents. Invest New Drugs (2009) 0.96
Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care. Br J Cancer (2010) 0.92
Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection? BMC Cancer (2011) 0.89
Assessment of nutritional status of gynecological cancer cases in India and comparison of subjective and objective nutrition assessment parameters. South Asian J Cancer (2014) 0.83
A clinical decision support tool to predict survival in cancer patients beyond 120 days after palliative chemotherapy. J Palliat Med (2012) 0.81
Development and validation of a bedside score to predict early death in cancer of unknown primary patients. PLoS One (2009) 0.80
Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials. Invest New Drugs (2009) 0.77
Factors influencing treatment selection and survival in advanced lung cancer. Curr Oncol (2017) 0.76
A Simple Risk Model to Predict Survival in Patients With Carcinoma of Unknown Primary Origin. Medicine (Baltimore) (2015) 0.75
A Prognostic Model in Metastatic or Recurrent Gastric Cancer Patients with Good Performance Status Who Received First-Line Chemotherapy. Transl Oncol (2016) 0.75
Development of a score that predicts survival among patients with bone metastasis revealing solid tumor. Support Care Cancer (2008) 0.75
Cancer-associated hypercalcemia: validation of a bedside prognostic score. Support Care Cancer (2009) 0.75
Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep (1966) 48.83
Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol (1995) 5.86
Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med (2005) 2.98
Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev (2006) 2.59
Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol (2000) 2.20
Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep (1986) 1.91
Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer (2006) 1.75
Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs (1991) 1.67
Responses and toxic deaths in phase I clinical trials. Ann Oncol (1990) 1.43
CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer (2004) 1.35
Race, nutritional status, and survival from breast cancer. J Natl Cancer Inst (1990) 1.23
Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer (2001) 1.21
Nutritional factors and survival of patients with oral cancer. Head Neck (2006) 1.17
Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. Radiother Oncol (2005) 1.16
Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience. Int J Oncol (1999) 1.10
Prognostic factors for survival in patients treated in phase I clinical trials. Cancer (1994) 0.98
Therapeutic and prognostic implications of peripheral blood lymphopenia in patients with Hodgkin's disease. Leuk Lymphoma (1999) 0.90
Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials. Cancer (2005) 0.89
A phase I trial on the ethics of phase I trials. J Clin Oncol (1995) 0.88
Phase I cancer trials: limitations and implications. Mol Biother (1992) 0.75
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol (2006) 4.87
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol (2008) 4.24
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol (2013) 2.41
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol (2010) 2.31
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol (2008) 1.76
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol (2005) 1.66
Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol (2006) 1.56
Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies--the Pre-Optimon study. Contemp Clin Trials (2010) 1.46
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist (2012) 1.34
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). Cancer (2013) 1.25
Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation. Cancer Res (2011) 1.20
Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clin Pathol (2012) 1.15
Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. Invest New Drugs (2009) 1.12
Frequency of certain established risk factors in soft tissue sarcomas in adults: a prospective descriptive study of 658 cases. Sarcoma (2008) 1.08
Partial breast irradiation as sole therapy for low risk breast carcinoma: early toxicity, cosmesis and quality of life results of a MammoSite brachytherapy phase II study. Radiother Oncol (2008) 1.03
Using Treemaps to represent medical data. Stud Health Technol Inform (2006) 1.02
DicomWorks: software for reviewing DICOM studies and promoting low-cost teleradiology. J Digit Imaging (2007) 1.01
Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis. Support Care Cancer (2007) 1.00
Data mining to generate adverse drug events detection rules. IEEE Trans Inf Technol Biomed (2011) 0.98
"Classical 3 + 3 design" versus "accelerated titration designs": analysis of 270 phase 1 trials investigating anti-cancer agents. Invest New Drugs (2009) 0.96
Prevention of surgical site infection after breast cancer surgery by targeted prophylaxis antibiotic in patients at high risk of surgical site infection. J Surg Oncol (2007) 0.96
Expression of Egfl7 correlates with low-grade invasive lesions in human breast cancer. Int J Oncol (2013) 0.95
Image-guided robotic stereotactic radiation therapy with fiducial-free tumor tracking for lung cancer. Radiat Oncol (2012) 0.95
Risk factors for early catheter-related infections in cancer patients. Cancer (2007) 0.94
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer (2013) 0.92
Prognosis of hypercalcemia in aerodigestive tract cancers: study of 136 recent cases. Oral Oncol (2005) 0.91
Data-mining-based detection of adverse drug events. Stud Health Technol Inform (2009) 0.91
Report of eight recent cases of locally advanced primary pulmonary artery sarcomas: failure of Doxorubicin-based chemotherapy. J Thorac Oncol (2008) 0.90
Factual understanding of randomized clinical trials: a multicenter case-control study in cancer patients. Invest New Drugs (2009) 0.90
Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse? Breast (2002) 0.89
Salvage intracerebrospinal fluid thiotepa in breast cancer-related leptomeningeal metastases: a retrospective case series. Anticancer Drugs (2013) 0.87
Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course. Breast Cancer Res Treat (2011) 0.87
Detection of adverse drug events: proposal of a data model. Stud Health Technol Inform (2009) 0.86
Prolonged survival of patients with breast cancer-related leptomeningeal metastases. Anticancer Res (2013) 0.85
Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs. Invest New Drugs (2010) 0.85
O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. Invest New Drugs (2008) 0.84
Assessing association rules and decision trees on analysis of diabetes data from the DiabCare program in France. Stud Health Technol Inform (2002) 0.84
Graphical representation of the comprehensive patient flow through the hospital. AMIA Annu Symp Proc (2007) 0.83
Leptomeningeal metastasis in melanoma: a prospective clinical study of nine patients. In Vivo (2012) 0.83
"Sufficient life expectancy": an amazing inclusion criterion in cancer phase II-III trials. J Clin Oncol (2009) 0.83
Return to work after treatment for breast cancer: single center experience in a cohort of 273 patients. Bull Cancer (2011) 0.82
Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: a case-control study. J Neurooncol (2011) 0.82
Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today? J Clin Oncol (2003) 0.82
Parvovirus H-1 induces cytopathic effects in breast carcinoma-derived cultures. Breast Cancer Res Treat (2009) 0.82
Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. Target Oncol (2013) 0.82
Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever. Support Care Cancer (2004) 0.81
Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. J Thorac Oncol (2008) 0.81
Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. Clin Cancer Res (2006) 0.81
Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint Bone Spine (2007) 0.81
Detection and prevention of Adverse Drug Events - information technologies and human factors. Preface. Stud Health Technol Inform (2009) 0.81
A simple predictive model for postoperative mortality after head and neck cancer surgery with opening of mucosa. Oral Oncol (2006) 0.81
Individual life expectancy estimation using validated prognostic scores for patients with cancer of unknown primary. Oncology (2010) 0.80
Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies. Clin Cancer Res (2005) 0.80
CSF CA 15-3 in breast cancer-related leptomeningeal metastases. J Neurooncol (2014) 0.80
A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy. Breast Cancer Res Treat (2015) 0.79
Relationships between progesterone receptor isoforms and the HER/ErbB receptors and ligands network in 299 primary breast cancers. Int J Biol Markers (2012) 0.79
Adverse drug events with hyperkalaemia during inpatient stays: evaluation of an automated method for retrospective detection in hospital databases. BMC Med Inform Decis Mak (2014) 0.79
Modelling a regional reorganization of cardiovascular surgery provision. Health Place (2005) 0.79
A statistics-based approach of contextualization for adverse drug events detection and prevention. Stud Health Technol Inform (2012) 0.79
Knowledge engineering for adverse drug event prevention: on the design and development of a uniform, contextualized and sustainable knowledge-based framework. J Biomed Inform (2012) 0.79
Adverse drug events prevention rules: multi-site evaluation of rules from various sources. Stud Health Technol Inform (2009) 0.78
Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials. Invest New Drugs (2010) 0.78
The quality of life of young women with nonmetastatic breast cancer and their partners': specific needs require development of specific questionnaires for each of them. Breast J (2012) 0.77
Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials. Invest New Drugs (2009) 0.77
Detection of adverse drug events detection: data aggregation and data mining. Stud Health Technol Inform (2009) 0.77
Interoperability of medical databases: construction of mapping between hospitals laboratory results assisted by automated comparison of their distributions. AMIA Annu Symp Proc (2011) 0.77
Decrease social inequalities return-to-work: development and design of a randomised controlled trial among women with breast cancer. BMC Cancer (2014) 0.76
Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome. BMC Cancer (2013) 0.76
Participation in randomised clinical trials is linked to emotion regulation strategies. Contemp Clin Trials (2010) 0.76
Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy. Invest New Drugs (2010) 0.76
[Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies]. Bull Cancer (2013) 0.76
Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. Med Oncol (2012) 0.75
[Adjuvant chemotherapy for breast cancer and fertility: estimation of the impact, options of preservation and role of the oncologist]. Bull Cancer (2011) 0.75
Role of the investigator in phase 1 trials of anticancer drugs. Lancet Oncol (2012) 0.75
Predictive value of clinical judgment of tumour progression in phase II trials. PLoS One (2012) 0.75
General practitioners assessment of a structured report on medical decision making by a regional multidisciplinary cancer committee. Bull Cancer (2007) 0.75
Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer. Bull Cancer (2012) 0.75
Regorafenib use as a possible cause of intestinal perforation. Acta Oncol (2013) 0.75
[Evaluation of cytological screening for cancers and precancerous lesions of the cervix]. Bull Cancer (2003) 0.75
First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control. Oncology (2016) 0.75
Group Decision Support System applied to the medical pluri-disciplinary decision group: usability and efficacy. Stud Health Technol Inform (2008) 0.75
Inflation in the number of eligibility criteria for industry-sponsored phase II cancer clinical trial: illustration over a 20-year period. Contemp Clin Trials (2012) 0.75
Toward automatic detection and prevention of adverse drug events. Stud Health Technol Inform (2009) 0.75
Development of a score that predicts survival among patients with bone metastasis revealing solid tumor. Support Care Cancer (2008) 0.75
Study on urban healthcare consumption in northern France. Stud Health Technol Inform (2008) 0.75
Similarity study on university teaching hospitals in France. Stud Health Technol Inform (2003) 0.75
An Internet supported workflow for the publication process in UMVF (French Virtual Medical University). Int J Med Inform (2007) 0.75